Table 1 Demographic characteristics, baseline characteristics, and clinical outcomes of patients with SARS-CoV 2 infection

Demographic characteristics, baseline characteristics

 Age, years

62 (52–68)

62 (51.5–72.5)

61 (52–66)

0.768

 Sex

 Men

66 (51.6)

10 (58.8)

56 (50.4)

0.520

 Women

62 (48.4)

7 (41.2)

55 (49.6)

0.520

 Symptoms

 Respiratory rate

25 (20–41)

25 (20–47.5)

25 (22.25–41.25)

0.849

 > 24 breaths per min

53 (41.4)

15 (88.2)

38 (34.2)

< 0.001*

 Systolic pressure, mmHg

133 (120–147)

127(116–152.25)

138 (122–148)

0.820

 SpO₂,%

93 (82–97)

95 (73.5–98.75)

92 (82–95)

0.752

 Heart rate

94 (86–99)

86 (84.5–106.5)

95 (93–100)

0.611

Laboratory test

 White blood cell count, × 10⁹/L

8.4 (4.6–10.8)

10.35 (7.925–13.25)

7.1 (4–9.1)

0.081

 Neutrophil %

89.2 (82.2–92)

91.2 (88.2–92.3)

88.9 (72.7–91.6)

0.288

 Lymphocyte count, × 10⁹/L

0.58 (0.4–0.67)

0.54 (0.335–0.6525)

0.59 (0.4–0.75)

0.0002**

 Lymphocyte%

6.14 (4.73–12.79)

5.013 (3.92–6.77)

6.42 (5.61–15.59)

0.278

 Platelet < 100 × 10⁹/L, %

8 (6.25)

2 (11.7)

6 (5.41)

0.313

 D-dimer, mg/L

6.07 (2.26–6.9)

6.67 (1.85-32.9)

4.26 (2.26–6.39)

< 0.0001**

 Fibrinogen, g/L

5.81 (4.92–6.32)

6.15 (5.6-6.52)

4.93 (4.625–6.23)

0.177

 Albumin, g/L

27.3 (25.2–29.7)

25.6 (22.65–28.42)

28.2 (26.9–30.2)

0.03*

 Potassium, mmol/L

3.6 (3.22–3.9)

3.6 (3.2–4.0)

3.515 (3.255–3.877)

0.910

 Calcium, mmol/L

1.81 (1.14–1.92)

1.91 (1.855–2)

1.18 (1.13–1.9)

< 0.001*

 Sodium, mmol/L

142 (141–145)

141 (140–141)

142 (141–145)

0.743

 Procalcitonin, µg/L

0.34 (0.135–0.88)

0.475 (0.31–1.72)

0.12 (0.07-0.12)

0.257

 C-reactive protein, mg/

121.8 (42.31–259.6)

262.4 (122.3–271)

53.9 (17.79–137)

0.004*

 pH

7.42 (7.39–7.49)

7.46 (7.39–7.46)

7.41 (7.385–7.47)

0.347

 PaO₂, mmHg

54(48.5-150.5)

49.0 (43–106)

57 (49.5–170)

0.432

 PaCO_2, mmHg

38.2 (34.4–42.15)

34.2(28.6–47.82)

38.8 (37.75–42.15)

0.483

 Lac, mmol/L

1.05 (0.625–1.65)

1 (0.6–1)

1.1 (0.6–1.85)

0.821

 HCO₃^–

24.75 (23.65–29.15)

26.2 (22.8–26.2)

24.1 (23.7–29)

0.726

Clinical outcomes

 Acute myocardial injury%

11 (8.59)

2 (11.76)

9 (8.11)

0.640

 Acute liver injury%

11 (8.59)

2 (11.76)

9 (8.11)

0.640

 Acute kidney injury%

12 (9.37)

2 (11.76)

10 (9.01)

0.661

 Sepsis%

10 (7.81)

2 (11.76)

8 (7.21)

0.621

 Respiratory failure%

50 (39.1)

13 (76.5)

37 (33.3)

0.001*

 ARDS%

53 (41.4)

15 (88.2)

38 (34.2)

< 0.001*

 Heart failure%

4 (3.12)

1(5.88)

3 (2.71)

0.439

 Septic shock%

4 (3.12)

0

4 (3.60)

1

 Coagulopathy%

1 (0.781)

1 (5.88)

0

0.133

 Secondary infection%

2 (1.56)

1 (5.88)

1 (0.90)

0.249

 Hypoproteinaemia%

59 (46.1)

15 (88.2)

44 (39.6)

< 0.001*

 Acidosis%

3 (2.34)

1 (5.88)

2 (1.80)

0.350

 28-day mortality%

14 (10.9)

5 (29.4)

9 (8.11)

0.0046*

 14-day mortality%

10 (7.81)

5 (29.4)

5 (4.5)

0.0046*